<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02215720</url>
  </required_header>
  <id_info>
    <org_study_id>2010-012275-88</org_study_id>
    <secondary_id>2010/1626</secondary_id>
    <nct_id>NCT02215720</nct_id>
  </id_info>
  <brief_title>Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors</brief_title>
  <acronym>TORERO</acronym>
  <official_title>Phase I Study of Temsirolimus and Cetuximab in Adults Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cetuximab is an EGFR inhibitor that has shown efficacy alone or in combination in colorectal&#xD;
      cancer or head and neck cancer in several phase II/III studies.&#xD;
&#xD;
      Temsirolimus is a new mTOR inhibitor that has shown interesting results in several Phase I/II&#xD;
      studies in advance kidney cancer of bad prognosis.&#xD;
&#xD;
      Study hypothesis is that combination of those two compounds and the inhibition of two&#xD;
      pathways at the same time will have more efficiency on tumoral growth than the inhibition of&#xD;
      those pathways in isolation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Assessed every every week from inclusion during the four first weeks then at week 8 then every 2 months until death or progression whichever comes first up to 24 months</time_frame>
    <description>Adverse effects will be assessed using NCI-CTC.AE v.4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Assessed every 2 cycles (44 days) from inclusion up to 24 months</time_frame>
    <description>Tumorous response will be assessed using RECIST criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Patients With Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Cetuximab + Temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab: 400mg/mÂ² IV for 120 minutes Temsirolimus: 15mg IV for 60 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Cetuximab + Temsirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <arm_group_label>Cetuximab + Temsirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with malignant tumor confirmed histologically or cytologically who does not&#xD;
             respond to usual therapeutics or for whom there is no curative treatment&#xD;
&#xD;
          -  Age &gt;/= 18 years&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
          -  Life expectancy &gt;/= 12 weeks&#xD;
&#xD;
          -  Grade &lt;/=1 for all adverse effects related to previous therapy or surgery (except for&#xD;
             alopecia)&#xD;
&#xD;
          -  Appropriate organic functions as defined:&#xD;
&#xD;
          -  ASAT and ALAT &lt;/= 2.5xLSN or ASAT and ALAT &lt;/= 5xLSN in case of inappropriate hepatic&#xD;
             function due to the underlying disease&#xD;
&#xD;
          -  Bilirubin &lt;/= 1.5xLSN&#xD;
&#xD;
          -  Albumin &gt;/= 3.0 g/dL&#xD;
&#xD;
          -  Neutrophil counts (PNN) &gt;/= 1 500/mL&#xD;
&#xD;
          -  Platelets &gt;/= 100 000/mL&#xD;
&#xD;
          -  Hemoglobin &gt;/= 9.0 g/dL&#xD;
&#xD;
          -  Creatinin &lt;/= 1.5xLSN&#xD;
&#xD;
          -  Cooperative patients able to respect the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment by chemotherapy, radiotherapy, surgery or the two compounds of the study&#xD;
             within 4 weeks before the inclusion&#xD;
&#xD;
          -  Previous treatment with an association of mTOR inhibitor or EGFR inhibitor&#xD;
&#xD;
          -  Diagnosis of a secondary cancer within the last 3 years except for a basal-cell&#xD;
             carcinoma, cutaneous spinocellular cancer or in situ carcinoma well treated&#xD;
&#xD;
          -  Grade &gt;/= 2 nephropathy according to NCI CTCAE&#xD;
&#xD;
          -  Current treatment with curative dose of coumadin or heparin of low molecular weight&#xD;
&#xD;
          -  Previous uncontrolled brain metastases, medullar compression or carcinomatosis&#xD;
             meningitis or any proof of leptomeningeal pathology or metastasis.&#xD;
&#xD;
          -  Presence of one og those pathologies during the last 12 months before the inclusion:&#xD;
&#xD;
          -  myocardial infarction&#xD;
&#xD;
          -  angina pectoris&#xD;
&#xD;
          -  bypass of coronal or peripheral arteries&#xD;
&#xD;
          -  heart failure&#xD;
&#xD;
          -  stroke&#xD;
&#xD;
          -  cerebral bleeding&#xD;
&#xD;
          -  pulmonary embolism&#xD;
&#xD;
          -  Grade 3 bleeding according to NCI CTCAE criteria less than 3 weeks before treatment&#xD;
             start&#xD;
&#xD;
          -  Uncontrolled high blood pressure (&gt;150/100mhHg)&#xD;
&#xD;
          -  Grade &gt;/=2 heart rate disorder, atrial fibrillation whichever the grade, lengthen of&#xD;
             QTC &gt;450 msec for male or &gt;470 msec for female.&#xD;
&#xD;
          -  Patients HIV positive&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patients with psychiatric disorder&#xD;
&#xD;
          -  Active alcoholism&#xD;
&#xD;
          -  Previous pulmonary interstitial disease&#xD;
&#xD;
          -  Previous hypersensitivity to antihistamine treatment and/or medical contraindication&#xD;
             for an antihistamine or corticoid treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>SORIA Jean Charles, MD, PhD</last_name>
    <phone>0142114291</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-charles.soria@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HASSELBERG Rudiger, MD,PhD</last_name>
    <phone>0142116250</phone>
    <phone_ext>+33</phone_ext>
    <email>rudgier.hasselberg@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudiger HASSELBERG</last_name>
      <phone>0142116250</phone>
      <phone_ext>+33</phone_ext>
      <email>rudiger.hasselberg@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Charles SORIA, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>August 8, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>February 9, 2016</last_update_submitted>
  <last_update_submitted_qc>February 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

